Severe Asthma ToolkitSevere Asthma Toolkit
HomeAboutSpecific PopulationsRegistriesContributorsContact
Twitter
  • What is Severe Asthma?
    • Overview
    • Definition
    • Prevalence & Burden
    • Pathophysiology
    • Symptoms
    • Severe Asthma Attacks / Exacerbations / Flare-ups
    • Asthma Phenotypes
  • Diagnosis & Assessment
    • Overview
    • Diagnosis Overview
    • Assessment Overview
    • Lung Function Assessments
    • Questionnaires
    • Allergy Assessments
    • Phenotyping
    • Bronchoscopy
    • Imaging
    • Occupational Asthma
  • Management
    • Overview
    • Asthma Education
      • About Severe Asthma
      • Asthma Pathophysiology
      • Medications Education
      • Self-Monitoring
      • Triggers
      • Review
    • Written Action Plans
    • Adherence
    • Inhaler Technique
    • Physical Activity & Exercise
    • Interdisciplinary Approach & Multidimensional Assessment
    • Referral
  • Medications
    • Overview
    • Relievers
    • Preventers / Controllers
    • Add-on Therapies
    • Monoclonal Antibodies
    • Bronchial Thermoplasty
  • Co-Morbidities
    • Overview
    • Pulmonary & Upper Airways
      • Allergic & Non-Allergic Rhinitis
      • Chronic Rhinosinusitis
      • Dysfunctional Breathing
      • Vocal Cord Dysfunction
      • Chronic Obstructive Pulmonary Disease
      • Bronchiectasis
      • Obstructive Sleep Apnoea
    • Extra-Pulmonary
      • Obesity
      • Anxiety & Depression
      • Gastro-oesophageal Reflux Disease (GORD)
      • Osteoporosis
      • Cardiovascular Disease & Metabolic Disease
  • Living with Severe Asthma
    • Overview
    • Daily Symptom Burden
    • Mental & Emotional Health
    • Intimacy & Relationships
    • Self-Management Support
    • Medication Use & Costs
    • Experience of Care
    • Experience of Asthma Attacks
    • Prognosis
  • Establishing a Clinic
    • Overview
    • Set-up
    • Staffing & Multidisciplinary Team Approach
    • Facilities
    • Delivery Approach
    • Tailored Referrals
    • Evaluation
    • Opportunities for Training & Research
    • Barriers & Hurdles
  • Paediatrics
    • Overview
    • Management in Paediatrics
    • Assessment in Paediatrics
    • Alternative Diagnosis & Co-Morbidities in Paediatrics
    • Psychosocial Issues in Paediatrics
    • Medications in Paediatrics
    • Asthma in the Adolescent Population
  • Resources
    • Overview
    • Clinic Recommendations
    • Infographics
    • Asthma Assessment Resources
    • Systematic & Multidimensional Assessment Resources
      • Airway Components
      • Comorbidity Components
      • Risk Factor Components
    • Translation & Implementation
    • Case Studies
    • Presentations
    • Videos
    • Relevant Links
    • Key References

Clinic Recommendations

Home Resources Clinic Recommendations

Severe Asthma Clinic Recommendations

Severe asthma clinic recommendations have been developed to inform the management and treatment of individuals with severe asthma. These resources are useful educational resources, and to inform practice in the clinic setting.

  • Inflammation Biomarkers in the Assessment and Management of Severe Asthma – Tools and Interpretation:

This document was developed by the Centre of Excellence in Severe Asthma. It provides an overview of fractional exhaled nitric oxide (FeNO) and eosinophil numbers as biomarkers to inform asthma management, including assessment approaches and interpretation of findings. Asthma is heterogeneous with different disease phenotypes. Recognition and assessment of phenotypes is necessary for targeted therapy. Biomarkers can provide information about mechanisms underlying symptoms.

Access here: https://www.severeasthma.org.au/biomarkers-recommendation/

  • Clinical Recommendations for The Use of Omalizumab In Severe Asthma:

This document was developed by the Centre of Excellence in Severe Asthma. It provides an overview of omalizumab treatment, eligibility criteria, enrolment, precautions/adverse effects and procedures for administration. This document has been developed as a guide only. Any local recommendations and requirements must be considered when implementing these recommendations into practice.

Access here: https://www.severeasthma.org.au/omalizumab/

  • Clinical Recommendations for The Use of Mepolizumab In Severe Asthma:

This document was developed by the Centre of Excellence in Severe Asthma. It provides an overview of mepolizumab treatment, eligibility criteria, enrolment, precautions/adverse effects and procedures for administration. This document has been developed as a guide only. Any local recommendations and requirements must be considered when implementing these recommendations into practice.

Access here: https://www.severeasthma.org.au/mepolizumab/

  • Clinical Recommendations for The Use of Benralizumab In Severe Asthma:

This document was developed by the Centre of Excellence in Severe Asthma. It provides an overview of benralizumab treatment, eligibility criteria, enrolment, precautions/adverse effects and procedures for administration. This document has been developed as a guide only. Any local recommendations and requirements must be considered when implementing these recommendations into practice.

Access here: https://www.severeasthma.org.au/benralizumab

  • Clinical Recommendations for The Use of Azithromcyin In Severe Asthma:

This document was developed by the Centre of Excellence in Severe Asthma. It provides an overview of azithromycin treatment, dosage, screening, monitoring and precautions/adverse effects. This document has been developed as a guide only. Any local recommendations and requirements must be considered when implementing these recommendations into practice. Note: The use of macrolide antibiotics, including azithromycin, for the treatment of asthma is off-label.

Access here: https://www.severeasthma.org.au/azithromycin

  • Initiation of Monoclonal Antibodies for Severe Asthma in Primary Care:

In some situations, the initiation and continued administration of monoclonal antibodies may be considered in primary care, provided specific conditions are met. This approach may be reasonable where the patient has to travel long distances to the specialist’s clinic or where no ready access to a day procedure unit or outpatient clinic is available. Recommendations on the conditions are included and this information is now included as an Appendix in our Clinical Recommendation documents.

Access here: https://www.severeasthma.org.au/initiation-in-primary-care/

  • Clinical Recommendations for COVID-19 in Severe Asthma: 

This document was developed by the Centre of Excellence in Severe Asthma. This clinical recommendation was developed to assist clinicians in the management of severe asthma in the context of COVID-19. This document has been developed as a guide only. Any local recommendations and requirements must be considered when implementing these recommendations into practice.

Access here: https://www.severeasthma.org.au/blog/2020/05/15/covid-19/

  •  Clinical Recommendations for Dupilumab: 

Dupilumab is an add-on maintenance PBS listed treatment for people with severe uncontrolled eosinophilic asthma or severe allergic asthma (aged 12 years and older). Dupilumab is also indicated and PBS-subsidised as maintenance therapy for people with oral corticosteroid dependent eosinophilic or allergic asthma, or chronic severe atopic dermatitis. It is also indicated for patients with chronic rhinosinusitis with nasal polyposis.

Access here: https://www.severeasthma.org.au/dupilumab/

Multidimensional Assessment & Treatment Recommendations:
Under development
Previous
Next

Last Updated on July 6, 2022

Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories

More results...

  • Overview
  • Clinic Recommendations
  • Infographics
  • Asthma Assessment Resources
  • Systematic & Multidimensional Assessment Resources
    • Airway Components
    • Comorbidity Components
    • Risk Factor Components (Including Self-Management)
  • Translation & Implementation
  • Case Studies
  • Presentations
  • Videos
  • Relevant Links
  • Key References

We want to know who accesses the Severe Asthma Toolkit and how it is used. Please complete our survey.

Responses will inform the continued development of the Severe Asthma Toolkit and future translation and implementation activities. Any feedback you provide will be greatly appreciated.

Complete Survey

  • Website Terms of Use
  • Website Survey
© Copyright 2018    CRICOS Provider Number 00109J    The University of Newcastle, Australia